VYNE Therapeutics Q2 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $198.000K Beat $110.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
VYNE Therapeutics (NASDAQ:VYNE) reported Q2 2024 GAAP EPS of $(0.22), missing the $(0.19) estimate by 15.79%. However, sales of $198.000K beat the $110.000K estimate by 80%, marking a 46.67% increase from the same period last year.
August 14, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VYNE Therapeutics reported a Q2 2024 GAAP EPS of $(0.22), missing the $(0.19) estimate by 15.79%. However, sales of $198.000K beat the $110.000K estimate by 80%, showing a 46.67% increase from the same period last year.
Despite missing EPS estimates, VYNE Therapeutics significantly outperformed in sales, beating estimates by 80% and showing a strong year-over-year growth of 46.67%. This positive sales performance is likely to outweigh the EPS miss in the short term, leading to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100